Adam Cunningham, Professor of Functional Immunity, speculates on how might the Omicron variant might affect future COVID-19 variants.
The University of Birmingham today announces the launch of five new major studies aimed at improving the prevention, treatment and management of type 1 diabetes – with a particular focus on children and young adults.
Elderly care home residents who have previously contracted and survived COVID-19 develop much stronger and higher antibody and cellular immune responses to two doses of vaccination, research finds.
LifeArc and PSC Support jointly award £898,774 for new research into primary sclerosing cholangitis (PSC), a rare disease where the body attacks its own liver, causing inflammation and scarring of the bile ducts.
University of Birmingham cancer experts have welcomed a £120,000 charity donation to purchase new equipment that will help to speed the development of new treatments which could save the lives of children and adults.
A University of Birmingham-led study has shown that a third of patients with the most common type of leukaemia fail to generate any measurable antibody response following two doses of COVID-19 vaccination.
Construction of No.1 Birmingham Health Innovation Campus (BHIC) in Selly Oak is underway, marking a major milestone for the region's rapidly growing life sciences sector.
New research suggests that skin cancer patients could have a better prognosis if their T cells send messages from five specific genes in their immune response to drugs given to treat the disease.
University of Birmingham researchers are part of a new study seeking to understand why some people become infected with COVID-19 after vaccination or prior infection while others do not.
Birmingham researchers partnered with Cancer Research UK in one of the first target identification projects for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer patients.
A new study carried out in collaboration with the University of Birmingham shows both short and long dosing schedules of the Pfizer COVID-19 vaccine generate strong antibody and T cell immune responses.
The Universities of Birmingham, Leicester and Nottingham have launched a partnership training the next generation of leading researchers the skills required to transform our understanding and treatment of disease.